Rochester, MN, United States of America

Fabrice Lucien


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Mind of Fabrice Lucien: Pioneering Cancer Treatment Methods

Introduction: Fabrice Lucien, an accomplished inventor based in Rochester, MN, has made significant strides in the field of oncology. With a focus on enhancing the effectiveness of chemotherapeutic drugs, he is dedicated to improving cancer treatment outcomes for patients. His innovative approach addresses the challenges associated with tumor cell resistance to medications.

Latest Patents: Fabrice Lucien holds a patent for "Methods of sensitizing tumor cells to weak base chemotherapeutic drugs." This groundbreaking invention encompasses a method that sensitizes tumor cells by administering an effective amount of a NHE6-RACK1 blocker. Additionally, his patent outlines a treatment regimen for cancer that includes both the NHE6-RACK1 blocker and a weak base chemotherapeutic drug. This approach not only aims to improve the efficacy of existing treatments but also introduces new possibilities for creating compositions and kits that facilitate this dual administration.

Career Highlights: Fabrice has built a reputation for his innovative contributions to cancer research at Socpra Sciences Santé Et Humaines S.e.c., significantly impacting the field of medical science. His dedication to advancing treatment methodologies demonstrates a deep commitment to patient care and scientific inquiry.

Collaborations: Throughout his career, Fabrice has collaborated with notable colleagues, including Claire Dubois and Pierre-Paul Pelletier. These partnerships have fostered an environment of creativity and knowledge exchange, enhancing the development of new therapeutic strategies in cancer treatment.

Conclusion: Fabrice Lucien exemplifies the spirit of innovation in the medical field through his groundbreaking patent aimed at enhancing cancer treatment. With his focused approach to sensitizing tumor cells and dedicated collaborations, he continues to contribute valuable advancements that hold the promise of better patient outcomes and novel therapeutic avenues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…